<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01769001</url>
  </required_header>
  <id_info>
    <org_study_id>PB-102-F02</org_study_id>
    <nct_id>NCT01769001</nct_id>
  </id_info>
  <brief_title>An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients</brief_title>
  <official_title>An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protalix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protalix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will be enrolled into one of three PRX-102 dosing groups (0.2 mg/kg, 1.0 mg/kg, 2.0
      mg/kg), to receive the same dose they had received in Phase 1/2 study PB-102-F01, and will
      continue to receive PRX-102 as an intravenous infusion every 2 weeks for 38 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be enrolled into one of three PRX-102 dosing groups (0.2 mg/kg, 1.0 mg/kg, 2.0
      mg/kg) to receive the same dose they had received in the Phase 1/2 study, PB-102-F01, and
      will continue to receive intravenous infusions of PRX-102 every 2 weeks for 38 weeks (9
      months).

      All exploratory endpoints that were evaluated during the Phase 1/2 study PB-102-F01 will
      continue to be assessed in the extension protocol (study PB-102-F02).

      The additional exploratory efficacy parameters that were evaluated at baseline of the Phase
      1/2 study PB-102-F01 as a reference point, before the initiation of treatment, will be
      evaluated after 3 months into the extension study (total treatment of 6 months). These
      parameters include Gb3 concentration in renal and skin tissues, LVM, MSSI and cardiac
      function tests (echocardiography and stress test). Cerebrovascular disease (clinical and MRI)
      will be evaluated at last infusion (total treatment of 12 months).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">March 6, 2016</completion_date>
  <primary_completion_date type="Actual">March 6, 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety</measure>
    <time_frame>38 weeks</time_frame>
    <description>Adverse events reported by the patient and from monitoring with clinical laboratory, physical examination, ECG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gb3 concentrations</measure>
    <time_frame>38 weeks</time_frame>
    <description>Gb3 concentrations in plasma and urine sediment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate</measure>
    <time_frame>38 weeks</time_frame>
    <description>Measurement of glomerular filtration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>38 weeks</time_frame>
    <description>Short term brief pain inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteinuria</measure>
    <time_frame>38 weeks</time_frame>
    <description>Measure of kidney function</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRX-102 1 mg/kg every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRX-102 2 mg/kg every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRX-102 0.2 mg/kg every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRX-102</intervention_name>
    <description>Comparison of different doses of drug</description>
    <arm_group_label>1 mg/kg</arm_group_label>
    <arm_group_label>2 mg/kg</arm_group_label>
    <arm_group_label>0.2 mg/kg</arm_group_label>
    <other_name>plant cell expressed recombinant human alpha-galactosidase-A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completion of Phase 1/2 study PB-102-F01

          -  The patient signs informed consent

          -  Female patients and male patients whose co-partners are of child-bearing potential
             agree to use a medically acceptable method of contraception, not including the rhythm
             method

        Exclusion Criteria:

          -  Pregnant or nursing

          -  Presence of any medical, emotional, behavioral or psychological condition that, in the
             judgment of the Investigator and/or Medical Director, would interfere with the
             patient's compliance with the requirements of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Einat Almon, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Protalix Biotherapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Human Genetics, Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Health Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Baylor Institute of Metabolic Disease</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>O &amp; O Alpan LLC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology and Clinical Research Private Institute</name>
      <address>
        <city>Asuncion</city>
        <country>Paraguay</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Dia Quiron Zaragoza</name>
      <address>
        <city>Zaragoza</city>
        <zip>50012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Paraguay</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2013</study_first_submitted>
  <study_first_submitted_qc>January 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2013</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fabry disease</keyword>
  <keyword>Alpha galactosidase deficiency</keyword>
  <keyword>Metabolic storage disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

